Cancer Research Targets Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 66, 9921, October 15, 2006. doi: 10.1158/0008-5472.CAN-06-0879
© 2006 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hyodo, F.
Right arrow Articles by Krishna, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hyodo, F.
Right arrow Articles by Krishna, M. C.

Cell, Tumor, and Stem Cell Biology

Probing the Intracellular Redox Status of Tumors with Magnetic Resonance Imaging and Redox-Sensitive Contrast Agents

Fuminori Hyodo, Ken-ichiro Matsumoto, Atsuko Matsumoto, James B. Mitchell and Murali C. Krishna

Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Murali C. Krishna, Building 10, Room B3B69, NIH, Bethesda, MD 20892-1002. Phone: 301-496-7511; Fax: 301-480-2238; E-mail: murali{at}helix.nih.gov.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 
Nitroxide radicals are paramagnetic contrast agents, used in magnetic resonance imaging (MRI), that also exert antioxidant effects. Participating in cellular redox reactions, they lose their ability to provide contrast as a function of time after administration. In this study, the rate of contrast loss was correlated to the reducing power of the tissue or the "redox status." The preferential reduction of nitroxides in tumors compared with normal tissue was observed by MRI. The influence of the structure of the nitroxide on the reduction rate was investigated by MRI using two cell-permeable nitroxides, 4-hydroxy-2,2,6,6,-tetramethyl-1-piperidynyloxyl (Tempol) and 3-carbamoyl-2,2,5,5-tetramethylpyrrolidine-1-oxyl (3CP), and one cell-impermeable nitroxide, 3-carboxy-2,2,5,5,5-tetramethylpyrrolidine-1-oxyl (3CxP). Pharmacokinetic images of these nitroxides in normal tissue, tumor, kidney, and artery regions in mice were simultaneously obtained using MRI. The decay of Tempol and 3CP in tumor tissue was significantly faster than in normal tissue. No significant change in the total nitroxide (oxidized + reduced forms) was noted from tissue extracts, suggesting that the loss in contrast as a function of time is a result of intracellular bioreduction. However, in the case of 3CxP (membrane impermeable), there was no difference in the reduction rates between normal and tumor tissue. The time course of T1 enhancement by 3CxP and the total amount of 3CxP (oxidized + reduced) in the femoral region showed similar pharmacokinetics. These results show that the differential bioreduction of cell-permeable nitroxides in tumor and normal tissue is supported by intracellular processes and the reduction rates are a means by which the intracellular redox status can be assessed noninvasively. (Cancer Res 2006; 66(20): 9921-8)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Conclusion
 References
 
Differences in the biochemical profile between benign and neoplastic tissue present important opportunities in diagnosis and prognostic evaluation (1, 2). Malignant cells exhibit several differences in the levels of endogenous molecules which reflect the differences in the metabolism and the energetics of a transformed cell (3, 4). Imaging techniques that can noninvasively distinguish these differences provide significant advantage for diagnosis, choice of treatment, and monitoring the efficacy of treatment (5, 6).

Cellular energy is derived from the transport of electrons through a series of oxidation reactions to inspired molecular oxygen, resulting in an overall reducing environment. Several redox couples exist in cells contributing to the overall redox status (7). GSH, NADH, and NADPH are a few examples of intracellular molecules, which, in coordination with the corresponding enzymatic cycles, collectively determine the global redox status of tissue (7). These redox couples are responsive to changes in oxidizing-reducing conditions which can result from changes in blood flow, oxygenation, and other variables (8, 9). Many of the biochemical mechanisms that underlie the observed metabolic differences between malignant and normal tissue are well understood, making it possible to profile tissues based on the relative levels of key metabolites (4).

Noninvasive imaging modalities capable of detecting the levels of individual molecules related to cellular metabolism can potentially provide diagnostic and prognostic information. Localized phosphorus-31 magnetic resonance spectroscopy (31P-MRS) has been successfully used to distinguish malignant tissue from benign tissue by monitoring levels of endogenous organic and inorganic phosphates indicative of the energetic status (3, 10). MRS imaging (MRSI) techniques, detecting 1H chemical shifts of endogenous intracellular molecules such as choline and citrate, have an advantage over 31P-MRS in terms of sensitivity and the capability to image. However, for both MRS and MRSI, the low levels of the metabolites being monitored may impose a limitation on the temporal and spatial resolutions.

In addition to biochemical differences from normal tissue, several, but not all, solid tumors exhibit hypoxic regions resulting from inadequate vasculature and/or compromised blood flow (11). These tumors, although exhibiting radiation resistance because of hypoxia, might be selectively sensitized by hypoxic cell cytotoxins (12). Thus, techniques that noninvasively distinguish biochemical/physiologic differences can provide a means to characterize malignant tissue with specificity and sensitivity. Radioactive tracers are also useful in providing functional/biochemical information in imaging modalities. The uptake and retention of the radiotracer 18-fluorodeoxyglucose in tumors is monitored by positron emission tomography imaging to differentiate benign lesions from malignant lesions (13, 14).

More recently, dynamic contrast–enhanced magnetic resonance imaging (MRI) is being successfully applied to identify tumors using T1 contrast agents such as Gd3+ complexes, which provide enhancement to MR images (15–17). This technique uses perfusion differences between benign and malignant tissue and therefore examines extracellular differences in tumor vasculature based on the characteristic time-intensity profiles (18). Because the contrast agent enhances the water/proton–based image intensity, temporal and spatial resolutions tend to be much better compared to MRSI. The image intensity monitored as a function of time with dynamic contrast–enhanced MRI after injecting the contrast agent provides information of the perfusion and clearance of the contrast agent. However, Gd3+ is biologically "redox-inert" and any time-dependent loss in contrast is solely by clearance, which is an advantage in perfusion studies. Because of their size, the Gd3+ complexes are restricted to extracellular regions and do not provide contrast from intracellular regions.

Nitroxides are stable organic free radicals having a single unpaired electron and are therefore capable of providing image contrast via shortening T1 similar to Gd3+ complexes (19, 20). Although nitroxides compare unfavorably to conventional T1 contrast agents such as Gd3+ complexes in terms of relaxivity, being cell permeable, their volume distribution is significantly greater (21, 22). This partially compensates for their lower relaxivity compared with the cell-impermeable gadolinium complexes and provides useful T1 contrast enhancement per unit volume similar to unchelated Mn2+ (23).

Nitroxides were initially evaluated as potential contrast agents in MRI and were found suboptimal in the 1980s because of their lower molar relaxivity compared with Gd3+ (19). In addition, the rapid bioreduction of the paramagnetic nitroxide to the corresponding diamagnetic hydroxylamine compromised their utility as contrast agents (24). However, their propensity to undergo bioreduction might provide useful information pertaining to tissue redox status, provided that sufficient contrast enhancement is available initially (25).

Nitroxides are redox-active species which can be oxidized or reduced by the corresponding reactants in cells (26). Nitroxides were shown to undergo oxidation to the corresponding oxoammonium by various oxidants such as hypervalent heme, HO2·, CO3–·, and NO2· radicals (27–30). Thus, in tumors, low levels of oxidative stress may generate these species, which can decrease the nitroxide levels faster than in normal tissue. Oxoammonium cations can be reduced to the nitroxide level by superoxide at diffusion-limited rates. Nitroxides can also be reduced to the corresponding hydroxylamines by reductants such as ascorbate, semiquinone radical, and also by intercepting reducing equivalents from the electron transport chain. The hydroxylamines, on the other hand, can be oxidized to the nitroxides in the presence of hydrogen peroxide and other oxidants such as transition metal complexes (31).

In cell culture experiments, nitroxides were found to undergo accelerated conversion to hydroxylamines under hypoxic conditions compared with normoxia (32). Furthermore, in normoxic cells, the conversion was significantly retarded when the thiol levels were depleted or in cells deficient in the enzyme glucose-6-phosphate dehydrogenase (9, 33). In in vivo studies, irrespective of whether nitroxide or hydroxylamine is administered, the ratio of the nitroxide/hydroxylamine is constant and depends on the redox status of the tissue (9, 34, 35). These observations suggest that nitroxides participate in cellular redox reactions and that their levels may be indicative of the global cellular redox status. Nitroxides also offer structural flexibility in that there are numerous derivatives available that can be directed to localize in specific subcellular compartments or be restricted to extracellular spaces (22, 36).

Earlier studies have shown that a cell-permeable nitroxide was reduced faster in tumor than in normal tissue (8, 9, 37). Therefore, monitoring the rate of transformation of suitable nitroxides to the corresponding diamagnetic species using MRI can provide in vivo assessment of redox status in a noninvasive manner. In this study, the structural determinants on the nitroxide ring influencing the reduction rates and their differences between tumor and normal tissue were investigated.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Conclusion
 References
 
Chemical
Carbamoyl-proxyl (3-carbamoyl-2,2,5,5-tetramethylpyrrolidine-1-oxyl; 3CP); carboxy-proxyl (3-carboxy-2,2,5,5,5-tetramethylpyrrolidine-1-oxyl; 3CxP); Tempol (4-hydroxy-2,2,6,6,-tetramethyl-1-piperidynyloxyl) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Deionized water (deionization by the Milli-Q system) was used for all experiments. Other materials used were of analytic grade.

Animal Studies
Female C3H mice were supplied by the Frederick Cancer Research Center, Animal Production (Frederick, MD). The mice were 6 to 8 weeks of age at the time of experimentation, weighing 20 to 30 g, and were housed, five per cage, in climate-controlled, circadian rhythm–adjusted rooms, and were allowed food and water ad libitum. All in vivo experiments were carried out in compliance with the Guide for the Care and Use of Laboratory Animal Resources (1996), National Research Council, and approved by the National Cancer Institute Animal Care and Use Committee. Tumor cells were injected s.c. as a single cell suspension of 106 squamous cell carcinoma (SCCVII) cells in the right hind leg. The tumors grew to a diameter of 1.5 cm (1,800 mm3) in ~10 days, at which time, all imaging experiments were carried out.

MRI and Pulse Sequence
MRI measurements were done with a 4.7 T scanner controlled with ParaVision 3.0.1 (Bruker BioSpin MRI GmbH, Rheinstetten, Germany). For T2 mapping, spin echo images were obtained using a multi-slice multi-echo (MSME) sequence with a 10-echo train and an echo time of 15 ms. The scan time for a T2 mapping image set (NEX = 1) by the MSME sequence was 10 minutes. Spoiled gradient echo (SPGR; also referred to as gradient echo fast imaging: repetition time (TR), 75 ms; echo time (TE), 3 ms; flip angle (FA), 45 degrees; NEX, 2) was employed to observe the T1 effect. The scan time for six slices with the SPGR sequence was 20 seconds. Other common image variables are as follows: image resolution was 256 x 256, field of view (FOV) was 7.0 x 7.0 cm, slice thickness was 2.0 mm.

"Redox phantom". Five phantom tubes were prepared as shown in Fig. 1B . Tube (i) contained PBS in the absence of Tempol. Tubes (ii), (iii), (iv), and (v) contained 2 mmol/L of Tempol in the presence of 0, 0.5, 1, and 2 mmol/L of ascorbic acid (AsA), respectively, and were horizontally set in the resonator. After the addition of the AsA/PBS (pH 7.4) solution using a SP-10 catheter from a syringe, the MRI measurement with SPGR was immediately started and continuously measured for up to 10 minutes. The experiments were repeated four times with freshly prepared solutions. Semilogarithmic plots of the time course of MRI signal change in the region of interest (ROI, 30 x 30 pixels) were used for decay rate calculation. The decay rates of tubes (iii), (iv), and (v) were calculated by using filled symbols (Fig. 1C). The MRI conditions used were as follows: TR, 75 ms; TE, 3 ms; FA, 45 degrees; NEX, 2; scan time, 20 seconds. Image resolution, 256 x 256; FOV was 3.2 x 3.2 cm; slice thickness was 2.0 mm.


Figure 1
View larger version (23K):
[in this window]
[in a new window]
  		Figure 1. A, reversible one-electron reduction-oxidation showing the interconversion between the oxidized nitroxide (EPR active) and the corresponding reduced hydroxylamine (EPR inactive). B, continuous T1-weighted MR images of the Tempol phantom by reaction of AsA. Tube i, PBS; tube ii, 2 mmol/L of Tempol; tube iii, 2 mmol/L of Tempol and 0.5 mmol/L of AsA; tube iv, 2 mmol/L of Tempol and 1 mmol/L of AsA; tube v, 2 mmol/L of Tempol and 2 mmol/L of AsA. After the addition of the AsA/PBS solution using SP-10 tubes, the MRI measurement was started immediately and continuously measured for up to 10 minutes. C, the decay curves of Tempol with AsA as a function of concentration (0.5, 1, and 2 mmol/L). The experiments were repeated four times using freshly prepared solutions. Semilogarithmic plots of the time course of MRI signal change in the ROI (30 x 30 pixels) were used for decay rate calculation using ImageJ software. Semilogarithmic plots for time course of average MRI signal change in the ROI. Decay rate constants were obtained from the slope of linear portion of the decay curves (n = 4).

 
To compare the decay rate between EPRI and MRI, the phantoms including 3CP and 5 or 10 mmol/L of the AsA solution were prepared (n = 3). After adding the AsA solution, the scan was immediately started and continuously measured using both modalities. After data acquisition, decay rates were obtained. The MRI conditions used were identical to the above conditions. EPRI data acquisition was carried out using a home-built 300 MHz CW EPR imager (38). A set of 12 projections was obtained every 1.9 minutes. Other EPR conditions were follows: microwave frequency, 300 MHz; microwave power, 10 mW; field modulation frequency, 13.5 kHz; field modulation amplitude, 0.8; time constant, 0.01 seconds; sweep width, 10 G; scan time, 2 seconds; field gradient, 2.5 G/cm; and number of averages, 1. EPR images were reconstructed on a 128 x 128 matrix by filtered back-projection with a Shepp-Logan filter. FOV was 4.0 x 4.0 cm.

In vivo MRI Experiments
Mice were anesthetized by isoflurane (1.5%) in medical air (700 mL/min) and secured on a special holder by adhesive skin tape, stomach-side down. A breathing sensor (SA Instruments, Inc., Stony Brook, NY) was placed on the back of the mice. A nonmagnetic temperature probe (FISO, Quebec, Canada) was used to monitor the rectal temperature of the mice. The tail vein was cannulated for the injection of contrast agent. The mouse was then placed in the resonator, which was previously warmed up using a hot water cycling pad. The resonator unit, including the mouse, was placed in the magnet bore. The MR measurements were started after the mouse's core body temperature stabilized to 37°C. The mouse body temperature was kept at 37 ± 1°C during the experiment. Before taking the measurements with the nitroxide contrast agents, native images of the mouse were taken with the variables mentioned above. The middle two slices including normal tissue, tumor tissue, kidney, and artery area, were selected as reference for calculating signal enhancement in the presence of the nitroxide agents. T1-weighted images were acquired continuously for 20 minutes, using SPGR. A solution of nitroxide contrast agent in PBS (1.5 µmol/g body weight) was injected via tail vein cannulation, 2 minutes after starting the scan.

Image Analysis
The MRI data were analyzed using the ImageJ software package.1 T2 maps were calculated using a plug-in (MRI analysis calculator, Karl Schmidt, HypX Laboratory, Brigham and Women's Hospital) available in ImageJ.

Total Tissue Nitroxide Concentration Assessment
Nitroxide contrast agents dissolved in PBS (pH 7.4) were injected into the tail vein of C3H mice bearing SCCVII tumors at a dose of 1.5 µmol/g body weight. The concentration in the bolus was 150 mmol/L for 3CxP and 300 mmol/L for Tempol and 3CP (three animals each). The blood and organs were collected and wet weight was determined at different times (2.5, 5, 7.5, 10, 15, and 20 minutes). Blood samples were diluted and tissue samples were homogenized with 4-fold volumes of PBS. Ferricyanide (200 µL of 10 mmol/L solution) was added to each sample solution (800 µL) to obtain the final concentration of 2 mmol/L. The ferricyanide quantitatively converts the hydroxylamine produced as a result of in vivo reduction back to the oxidized form (27–29). The signal intensities of the 100 µL samples were measured using a Varian E-9 X-band EPR spectrometer. The EPR spectrometer operating conditions were: modulation frequency, 100 kHz; microwave power, 1 mW. Because there is linearity up to 2 mmol/L between the concentration and EPR signal magnitude of nitroxide contrast agents (data not shown), EPR signal magnitudes of homogenate mixtures were converted to the concentration using previously obtained standard curves (100 µmol/L-2 mmol/L). Finally, nitroxide concentrations in the tissues were calculated based on a dilution factor of 4.

Statistical Analyses
The statistical differences were estimated with the TTEST function in Microsoft Excel XP. The suitable "type" and "tail" for the test was selected according to the correspondence and variance of the data. Significances were estimated at P < 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Conclusion
 References
 
The two cell-permeable nitroxides, Tempol and 3CP, exhibit amphipathic behavior, whereas the cell-impermeable nitroxide, 3CxP, exhibits minimal lipophilicity. The relaxivity differences were minimal between the three nitroxides and were ~0.2 mmol/L–1 s–1. Phantom experiments were carried out to examine the capability of Tempol to participate in redox reactions and elicit time-dependent changes in image contrast using AsA as a model reductant, which can convert the paramagnetic nitroxide molecule to the corresponding diamagnetic hydroxylamine (Fig. 1A). Figure 1B (left) shows the schematics of the five-tube phantom used. Tube (i) is a PBS solution with no additives. Tubes (ii), (iii), (iv), and (v) contained 2 mmol/L of Tempol in the presence of 0, 0.5, 1, and 2 mmol/L AsA, respectively. T1-weighted MRI images were collected using the SPGR sequence at different times after the reaction was initiated. As expected, no enhancement in intensity was observed in tube (i), in which Tempol was not included. In tube (ii), which contained 2 mmol/L of Tempol, a significant enhancement in image intensity was noted, which did not change with time, consistent with the notion that no reduction reaction takes place in the absence of AsA. However, in tubes (iii), (iv), and (v), which contained AsA and Tempol, a time-dependent loss in image intensity was noticed. The rate at which the intensity decreased in these tubes was dependent on AsA concentration. Tube (v), which contained Tempol in the presence of 2 mmol/L of AsA, exhibited a loss in intensity characterized by a rate constant of k = 0.33 ± 0.03 min–1, whereas tubes (iii) and (iv), which had 0.5 or 1 mmol/L of AsA, exhibited a reduction constant rate of k = 0.07 ± 0.02 min–1 and k = 0.18 ± 0.03 min–1, respectively, suggesting that the reduction rate was directly dependent on the concentration of the reductant (Fig. 1C). To compare the decay rate between EPRI and MRI, 3CP and AsA (5 and 10 mmol/L) phantoms were prepared. The decay rate constants, obtained using both modalities, were similar (5 mmol/L of AsA: EPRI, 0.066 ± 0.004 min–1; MRI, 0.007 ± 0.007 min–1; 10 mmol/L of AsA: EPRI, 0.136 ± 0.009 min–1; MRI, 0.130 ± 0.006 min–1) and changed as a function of AsA concentration (Table 1 ). These results show that MRI decay rates can validly extract the reduction rates of 3CP to hydroxylamine as well as EPRI. The in vivo data with 3CP using MRI also showed that MR signal change between normal and tumor tissue was similar to EPRI (Table 1; ref. 25).


View this table:
[in this window]
[in a new window]
  		Table 1. Decay constant of 3CP with AsA by means of EPR spectroscopy, EPRI, and MRI

 
The pharmacokinetic MR images of the three nitroxides were simultaneously examined in normal tissue, tumor tissue, kidney, and artery area using SPGR to acquire six slices every 20 seconds. Two middle slices were considered because they could be used to visualize the target organs (normal tissue, tumor tissue, kidney, and blood). Figure 2 shows slice 1 containing normal tissue and tumor tissue at several time points after the injection of three different nitroxide radicals. As can be seen, a time-dependent increase in image intensity, indicating the accumulation of these agents, was observed. However, each individual nitroxide exhibited different times to reach a peak value in intensity enhancement, as well as temporally different patterns of tumor enhancement. In the case of Tempol, a modest enhancement in intensity in all the tissues was observed as early as 30 seconds after injection, followed by a rapid loss in enhancement, and after 2.8 minutes, those changes were no longer observed (Figs. 2A and 3A ). Interestingly, the area of signal increase in tumor tissue displayed an inhomogeneous pattern. However, in the case of 3CP, the contrast in tumor tissue increased until 2.8 minutes after injection, and its distribution was homogeneous. A decrease in image intensity was observed after 7.8 minutes, in contrast to Tempol, in which the intensity decrease was noticed at earlier times. The images in the kidney and artery area also showed enhancement, which decreased as a function of time. On the other hand, when the cell-impermeable 3CxP was injected, the accumulation in tissues was very slow and the enhancement was high compared with other nitroxides. The maximum intensity in tumor area was noticed at 9.3 minutes after injecting 3CxP. Figure 3 shows slice 2, containing kidney and artery areas at time points corresponding to those in Fig. 2. The kidney area showed continuous enhancement up to 17.8 minutes.


Figure 2
View larger version (45K):
[in this window]
[in a new window]
  		Figure 2. Comparison of pharmacokinetic/redox images (slice 1) of three nitroxide contrast agents by SPGR MRI. Sixty serial images of Tempol (A), 3CP (B), and 3CxP (C) were obtained during 20 minutes of continuous imaging. Slice 1, normal and tumor tissue area. Enhanced image intensity (%) against preinjection image by T1-weighted MRI (green). D, for T2 mapping, spin echo images were obtained using a MSME sequence with eight echo trains and 15-ms echo times.

 

Figure 3
View larger version (33K):
[in this window]
[in a new window]
  		Figure 3. Comparison of pharmacokinetic/redox images (slice 2) of three nitroxide contrast agents using SPGR MRI. The 60 serial images of Tempol (A), 3CP (B), and 3CxP (C) were obtained for 20 minutes. Slice 2, kidney and artery area. Enhanced image intensity (%) against preinjection images (green).

 
Figure 2D shows an example of a T2 map generated from slice 1, containing muscle and tumor tissue. To monitor the reduction rates of the three nitroxides, a single ROI was selected on the T2 map. The decay rates of signal intensity within each ROI, after administration of the three nitroxides, were obtained from 60 SPGR images. Table 2 shows the results of the above experiments, involving three animals injected with each of the three nitroxide analogues. The two cell-permeable nitroxides, Tempol and 3CP, exhibited distinct differences in the decay rates of image intensity between normal and tumor tissue. In the case of Tempol, the decay rate in the tumor was ~3.5 times that observed in the normal tissue. For 3CP, the decay rate in the tumor was ~2 times higher than in the normal leg. However, in the case of the cell-impermeable nitroxide, 3CxP, no significant differences in signal decay rates between tumor and muscle tissue were detected. When the signal decay rates of the three nitroxides in the normal leg were compared, they ranked, from fastest to slowest (Tempol >> 3CP > 3CxP). The levels of nitroxide + hydroxylamine as a function of time after i.v. administration of the three nitroxides were examined by analyzing the tissue extracts after oxidation with ferricyanide using EPR spectroscopy. The results of EPR analysis are summarized in Fig. 4 . Although Figs. 2 and 3 show that MR image intensity decays in both tumor and normal muscle, the total (nitroxide + hydroxylamine) does not change significantly during the imaging time in either tumor or muscle. Furthermore, similar patterns were observed in blood and kidney levels in which the MR intensity exhibited a rapid decay as a function of time, whereas the total levels remained unchanged. It was suggested that the decrease in image intensity observed in T1-weighted imaging is associated with the bioreduction of nitroxides predominantly in the imaging time windows. Furthermore, the contributions of clearance of nitroxide to the observed intensity decay rates were minimal. Intracellular reducing equivalents and electrons intercepted from the mitochondrial electron transport chain were proposed as the mechanisms which underlie the reduction of nitroxides (32, 39).


View this table:
[in this window]
[in a new window]
  		Table 2. Decay rate of nitroxide contrast agents in various tissues

 

Figure 4
View larger version (36K):
[in this window]
[in a new window]
  		Figure 4. The pharmacokinetics of oxidized form and total (oxidized and reduced form) nitroxide contrast agents in normal tissue, tumor tissue, blood, and kidney area. The pharmacokinetics of the oxidized form of Tempol (A), 3CP (B), and 3CxP (C) in normal tissue (blue), tumor tissue (purple), artery (red), and kidney area (left kidney, dark green; right kidney, light green) were obtained by SPGR MRI. The total nitroxide contrast agent concentration of Tempol (A), 3CP (B), and 3CxP (C) in normal tissue (top, gray), tumor tissue (top, black), blood (middle), and kidney (bottom) were measured by X-band EPR spectroscopy using 10 mmol/L of ferricyanide/PBS solution (final concentration was 2 mmol/L).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Conclusion
 References
 
Tumors and normal tissue may differ in several physiologic properties including oxygen status, reducing capability, pH, interstitial pressure, etc. (11). These differences can, at least in part, be attributed to the compromised blood flow and leaky vasculature in tumors (12). Furthermore, differences between intracellular and extracellular pH may have a profound influence on the uptake of exogenous molecules including chemotherapy drugs and intracellular contrast agents, such as the nitroxide radicals, by providing conditions favoring the uptake of weakly acidic drugs (40). Treatment strategies that exploit such differences, such as hypoxic cell cytotoxins, are being explored (41). Imaging modalities that can detect such subtle differences will aid in the development of appropriate treatment strategies (5).

MRI-based techniques such as MRS and MRSI can detect levels of endogenous metabolites that reflect the tissue redox status (1). These techniques, which have been shown to be of significant diagnostic value, were used to successfully monitor treatment progress (5, 42). However, the low levels of the metabolites impose limitations on the resolution (temporal and spatial) achievable with MRS and MRSI. Paramagnetic contrast agents in MRI provide information on tumor perfusion (16). However, clinically used contrast agents are extracellular, do not participate in redox reactions, and are therefore insensitive to tissue redox status.

Nitroxides have a combination of unique properties that make them promising candidates as redox status–sensitive MRI contrast agents. The paramagnetic nitroxide radicals can undergo reduction to the corresponding diamagnetic hydroxylamine, which can revert to the nitroxide in the presence of oxidants or if the cellular oxygen status permits (27, 31). The nitroxide reduction is supported by intracellular enzymatic processes, and is more efficient in hypoxic cells than in aerobic cells (43, 44). They are also effective antioxidants, which offer protection to cells in culture and were used successfully in animals exposed to diverse types of oxidative insult (26). Earlier studies established the feasibility of using MRI to monitor the spatial distribution of nitroxides and their redox transformations in vivo with high spatial and temporal resolution (25).

Several studies showed that thiol-dependent processes contribute, at least in part, to in vivo nitroxide reduction (9, 45). Earlier studies using EPR spectroscopy in cellular incubations of nitroxides, the cell-permeable nitroxides, Tempol and 3CP, were found to accumulate intracellularly, whereas 3CxP was not detectable from intracellular regions even after prolonged incubations. However, anionic transport pathways for 3CxP cannot be ruled out. Additionally, the accumulation of nitroxides in extracellular spaces as a result of leaky vasculature may make the clearance pathways of nitroxides less efficient. In this study, an established EPR method of invasively detecting total nitroxide/hydroxylamine levels was used to show that SPGR MRI signal intensity loss, after nitroxide injection, is not due to washout. The combination of the nitroxide contrast agent and SPGR MRI studies provided us with pharmacokinetic information for various tissues. The availability of anatomic information, as well as the superior spatial and temporal resolution, make MRI more efficient at monitoring the pharmacokinetic properties of nitroxides compared with EPR imaging methods.

The MRI studies clearly show that among the nitroxides tested, the six-membered piperidine nitroxide, Tempol, was reduced rapidly compared with the two five-membered pyrrolidine nitroxides, 3CP and 3CxP. Tempol and 3CP (both cell permeable) were reduced in tumors more rapidly than in normal muscle. However, the cell-impermeable nitroxide, 3CxP, exhibited no difference between tumor and normal tissue. To determine the contribution of clearance processes to the time-dependent signal intensity loss in MRI experiments, ex vivo EPR analyses of tissues from an independent set of animals were done. EPR studies show that during the scan time of 20 minutes, the total (nitroxide + hydroxylamine) levels remained unchanged, suggesting that clearance is not a major contributor to the observed time-dependent intensity change. Importantly, the data further indicates that the observed time-dependent disappearance of MR image intensity enhancement due to Tempol and 3CP (both cell permeable) in various tissues occurred as a result of intracellular reduction.


   Conclusion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
References
 
In this study, we have shown that the pharmacokinetics of nitroxide contrast agents and high-quality anatomic structure using SPGR MRI could be simultaneously acquired. Such information could be extremely useful to noninvasively monitor the intracellular redox status in various tissues, and to outline the redox differences between normal and tumor tissue. Nitroxide contrast agents such as Tempol and 3CP show significant differences in decay rates between normal and tumor tissues depending on the ability of nitroxides to cross the cellular membrane. The decay rate of Tempol in tumor tissue was fastest among the three nitroxide contrast agents compared with normal tissue. However, there was no difference between normal and tumor tissues in the case of 3CxP. The data from the current study fully supports the use of cell-permeable nitroxides coupled with MRI to noninvasively examine differences in the redox status of tissues. Although, in the present study, particular emphasis was placed on differences in the redox status in tumors compared with selected normal tissues, the technique possesses the potential to have broad applications to the study of other disease states, inflammatory processes, and other circumstances in which oxidative stress is implicated.


   Acknowledgments
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
1 http://rsb.info.nih.gov/ij/. Back

Received 3/14/06. Revised 7/25/06. Accepted 8/14/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 

  1. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res 2001;3:36–40.[CrossRef][Medline]
  2. Bhujwalla ZM, Artemov D, Aboagye E, et al. The physiological environment in cancer vascularization, invasion and metastasis [discussion 45, 152–3]. Novartis Found Symp 2001;240:23–38.[Medline]
  3. Bolan PJ, Nelson MT, Yee D, Garwood M. Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res 2005;7:149–52.[CrossRef][Medline]
  4. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002;16:451–63.[CrossRef][Medline]
  5. Bolan PJ, Meisamy S, Baker EH, et al. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003;50:1134–43.[CrossRef][Medline]
  6. Li X, Jin H, Lu Y, Oh J, Chang S, Nelson SJ. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004;17:10–20.[CrossRef][Medline]
  7. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001;30:1191–212.[CrossRef][Medline]
  8. Kuppusamy P, Afeworki M, Shankar RA, et al. In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. Cancer Res 1998;58:1562–8.[Abstract/Free Full Text]
  9. Kuppusamy P, Li H, Ilangovan G, et al. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res 2002;62:307–12.[Abstract/Free Full Text]
  10. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811–5.[Abstract/Free Full Text]
  11. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408–16.[Abstract/Free Full Text]
  12. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437–47.[CrossRef][Medline]
  13. Benard F, Turcotte E. Imaging in breast cancer: single-photon computed tomography and positron-emission tomography. Breast Cancer Res 2005;7:153–62.[CrossRef][Medline]
  14. Verreault J, Turcotte E, Benard F, Mongeau CJ, Boileau R. Extensive F-18 FDG uptake in metastatic spindle cell carcinoma of the lung. Clin Nucl Med 2001;26:79–80.[CrossRef][Medline]
  15. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002;15:154–63.[CrossRef][Medline]
  16. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002;16:407–22.[CrossRef][Medline]
  17. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005;30:324–41.[Medline]
  18. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003;17:509–20.[CrossRef][Medline]
  19. Brasch RC, London DA, Wesbey GE, et al. Work in progress: nuclear magnetic resonance study of a paramagnetic nitroxide contrast agent for enhancement of renal structures in experimental animals. Radiology 1983;147:773–9.[Abstract/Free Full Text]
  20. Brasch RC, Nitecki DE, Brant-Zawadzki M, et al. Brain nuclear magnetic resonance imaging enhanced by a paramagnetic nitroxide contrast agent: preliminary report. AJR Am J Roentgenol 1983;141:1019–23.[Abstract/Free Full Text]
  21. Hahn SM, Wilson L, Krishna CM, et al. Identification of nitroxide radioprotectors. Radiat Res 1992;132:87–93.[Medline]
  22. Samuni AM, DeGraff W, Krishna MC, Mitchell JB. Cellular sites of H2O2-induced damage and their protection by nitroxides. Biochim Biophys Acta 2001;1525:70–6.[Medline]
  23. Koretsky AP, Silva AC. Manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed 2004;17:527–31.[CrossRef][Medline]
  24. Keana JF, Pou S. Nitroxide-doped liposomes containing entrapped oxidant: an approach to the "reduction problem" of nitroxides as MRI contrast agents. Physiol Chem Phys Med NMR 1985;17:235–40.[Medline]
  25. Matsumoto K, Hyodo F, Matsumoto A, et al. High-resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents. Clin Cancer Res 2006;12:2455–62.[Abstract/Free Full Text]
  26. Mitchell JB, Russo A, Kuppusamy P, Krishna MC. Radiation, radicals, and images. Ann N Y Acad Sci 2000;899:28–43.[Medline]
  27. Krishna MC, Grahame DA, Samuni A, Mitchell JB, Russo A. Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proc Natl Acad Sci U S A 1992;89:5537–41.[Abstract/Free Full Text]
  28. Krishna MC, Russo A, Mitchell JB, Goldstein S, Dafni H, Samuni A. Do nitroxide antioxidants act as scavengers of O2·. or as SOD mimics? J Biol Chem 1996;271:26026–31.[Abstract/Free Full Text]
  29. Krishna MC, Samuni A, Taira J, Goldstein S, Mitchell JB, Russo A. Stimulation by nitroxides of catalase-like activity of hemeproteins. Kinetics and mechanism. J Biol Chem 1996;271:26018–25.[Abstract/Free Full Text]
  30. Goldstein S, Samuni A, Hideg K, Merenyi G. Structure-activity relationship of cyclic nitroxides as SOD mimics and scavengers of nitrogen dioxide and carbonate radicals. J Phys Chem A Mol Spectrosc Kinet Environ Gen Theory 2006;110:3679–85.
  31. Dikalov S, Grigor'ev IA, Voinov M, Bassenge E. Detection of superoxide radicals and peroxynitrite by 1-hydroxy-4-phosphonooxy-2,2,6,6-tetramethylpiperidine: quantification of extracellular superoxide radicals formation. Biochem Biophys Res Commun 1998;248:211–5.[CrossRef][Medline]
  32. Chen K, Glockner JF, Morse PD II, Swartz HM. Effects of oxygen on the metabolism of nitroxide spin labels in cells. Biochemistry 1989;28:2496–501.[CrossRef][Medline]
  33. Samuni Y, Gamson J, Samuni A, et al. Factors influencing nitroxide reduction and cytotoxicity in vitro. Antioxid Redox Signal 2004;6:587–95.[CrossRef][Medline]
  34. Kuppusamy P, Chzhan M, Wang P, Zweier JL. Three-dimensional gated EPR imaging of the beating heart: time-resolved measurements of free radical distribution during the cardiac contractile cycle. Magn Reson Med 1996;35:323–8.[Medline]
  35. Hahn SM, Krishna MC, DeLuca AM, Coffin D, Mitchell JB. Evaluation of the hydroxylamine Tempol-H as an in vivo radioprotector. Free Radic Biol Med 2000;28:953–8.[CrossRef][Medline]
  36. Krishna MC, DeGraff W, Hankovszky OH, et al. Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage. J Med Chem 1998;41:3477–92.[CrossRef][Medline]
  37. Hahn SM, Krishna CM, Samuni A, et al. Potential use of nitroxides in radiation oncology. Cancer Res 1994;54:2006–10s.
  38. Koscielniak J, Devasahayam N, Moni MS, et al. 300 MHz continuous wave electron paramagnetic resonance spectrometer for small animal in vivo imaging. Rev Sci Instrum 2000;71:4273–81.[CrossRef]
  39. Chen K, Morse PD II, Swartz HM. Kinetics of enzyme-mediated reduction of lipid soluble nitroxide spin labels by living cells. Biochim Biophys Acta 1988;943:477–84.[Medline]
  40. Prescott DM, Charles HC, Poulson JM, et al. The relationship between intracellular and extracellular pH in spontaneous canine tumors. Clin Cancer Res 2000;6:2501–5.[Abstract/Free Full Text]
  41. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000;6:157–62.[CrossRef][Medline]
  42. Kurhanewicz J, Vigneron DB, Hricak H, et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 1996;200:489–96.[Abstract/Free Full Text]
  43. Swartz HM, Chen K, Pals M, Sentjurc M, Morse PD, II. Hypoxia-sensitive NMR contrast agents. Magn Reson Med 1986;3:169–74.[Medline]
  44. Swartz HM, Sentjurc M, Morse PD II. Cellular metabolism of water-soluble nitroxides: effect on rate of reduction of cell/nitroxide ratio, oxygen concentrations and permeability of nitroxides. Biochim Biophys Acta 1986;888:82–90.[Medline]
  45. Yamada KI, Kuppusamy P, English S, et al. Feasibility and assessment of non-invasive in vivo redox status using electron paramagnetic resonance imaging. Acta Radiol 2002;43:433–40.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
C. S. Wilcox and A. Pearlman
Chemistry and Antihypertensive Effects of Tempol and Other Nitroxides
Pharmacol. Rev., December 1, 2008; 60(4): 418 - 469.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. C. Ghosh, W.-H. Tong, D. Zhang, H. Ollivierre-Wilson, A. Singh, M. C. Krishna, J. B. Mitchell, and T. A. Rouault
Tempol-mediated activation of latent iron regulatory protein activity prevents symptoms of neurodegenerative disease in IRP2 knockout mice
PNAS, August 19, 2008; 105(33): 12028 - 12033.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. P. Cotrim, F. Hyodo, K.-I. Matsumoto, A. L. Sowers, J. A. Cook, B. J. Baum, M. C. Krishna, and J. B. Mitchell
Differential Radiation Protection of Salivary Glands versus Tumor by Tempol with Accompanying Tissue Assessment of Tempol by Magnetic Resonance Imaging
Clin. Cancer Res., August 15, 2007; 13(16): 4928 - 4933.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hyodo, F.
Right arrow Articles by Krishna, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hyodo, F.
Right arrow Articles by Krishna, M. C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online